Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Inovio Pharmaceuticals (NASDAQ:INO) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.23, Zacks reports.

Inovio Pharmaceuticals Stock Down 1.2 %

Inovio Pharmaceuticals stock traded down $0.03 during trading hours on Tuesday, hitting $2.09. The stock had a trading volume of 500,586 shares, compared to its average volume of 539,743. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The company has a market cap of $54.42 million, a PE ratio of -0.99 and a beta of 0.92. The company has a 50-day moving average of $2.05 and a two-hundred day moving average of $3.81.

Analyst Ratings Changes

INO has been the topic of a number of research analyst reports. HC Wainwright lowered their price target on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Finally, Oppenheimer reduced their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Inovio Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $12.40.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.